New Monoclonal Antibodies & Immunotherapies treatments in trials
Pembrolizumab, Nivolumab, Adalimumab — targeted oncology & autoimmune biologics. Track the treatments still in clinical testing and see which are closest to an FDA decision.
1,571Closest to approval (Phase 3)
5,852Mid-stage (Phase 2)
3,703Early stage (Phase 1)
18,802Total recruiting
In one line
18,802 monoclonal antibodies & immunotherapies trials are recruiting right now, 1,571 of them in Phase 3 — the stage immediately before an FDA decision.
Recruiting now
Twelve of the currently recruiting studies. Open one for a plain-English summary of who it is for and what it involves.
NCT06473259RecruitingEvaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer PatientsSummary NCT06647862Phase 3RecruitingIMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)Summary NCT07431788NARecruitingThe Effect of Uterine Manipulator Use During Abdominal Hysterectomy on Postoperative Sexual FunctionSummary NCT06001788Phase 1RecruitingSafety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaSummary NCT07200427NARecruitingMELIORA Virtual Coach Intervention for Breast Cancer PreventionSummary NCT04389086Phase 3RecruitingInduction Chemotherapy for Locally Recurrent Rectal CancerSummary NCT05429970NARecruitingA Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)Summary NCT06091254Phase 3RecruitingA Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaSummary NCT07426822Phase 2RecruitingRash & Diarrhea Prophylaxis With CapivasertibSummary NCT04550845NARecruitingUnderstanding of Genetics by Men at Risk for Prostate CancerSummary NCT06600659RecruitingA Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia AsparaginaseSummary NCT05236946Phase 3RecruitingObservation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCTSummary
Already approved for this area
Monoclonal Antibodies / Immunotherapies
Keytruda, Opdivo, Humira, Dupixent — approved products with their NDC records and billing codes.
Open the class
Every NDC in this class
The FDA registry filtered to monoclonal antibodies / immunotherapies, with packaging and 11-digit billing conversions.
Search the directory
Loading the trial explorer…